- Previous Close
1.2350 - Open
1.2100 - Bid 1.1800 x 100
- Ask 1.2700 x 100
- Day's Range
1.2000 - 1.2700 - 52 Week Range
1.1450 - 6.5000 - Volume
75,377 - Avg. Volume
245,476 - Market Cap (intraday)
48.648M - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3300 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.80
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
www.telabio.comRecent News: TELA
View MorePerformance Overview: TELA
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TELA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TELA
View MoreValuation Measures
Market Cap
48.85M
Enterprise Value
37.84M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.51
Price/Book (mrq)
1.72
Enterprise Value/Revenue
0.55
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-54.61%
Return on Assets (ttm)
-31.66%
Return on Equity (ttm)
-159.87%
Revenue (ttm)
69.3M
Net Income Avi to Common (ttm)
-37.84M
Diluted EPS (ttm)
-1.3300
Balance Sheet and Cash Flow
Total Cash (mrq)
52.67M
Total Debt/Equity (mrq)
151.31%
Levered Free Cash Flow (ttm)
-26.73M